47 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: 5-azacytidine;   Drug: Nivolumab;   Behavioral: Phone Call
2 Recruiting Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: nab-Paclitaxel;   Drug: Nivolumab;   Drug: Gemcitabine;   Drug: Carboplatin
3 Recruiting Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab
4 Not yet recruiting Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: Temozolomide;   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
5 Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Erlotinib;   Biological: Ipilimumab
6 Not yet recruiting Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Conditions: Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma
Interventions: Biological: Nivolumab;   Other: Laboratory Biomarker Analysis
7 Recruiting Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Condition: Kidney Cancer
Interventions: Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Ipilimumab
8 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
9 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia
Interventions: Biological: Nivolumab;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis
10 Not yet recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Sargramostim;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
11 Recruiting GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Condition: Previously Treated Metastatic Adenocarcinoma of the Pancreas
Interventions: Biological: CRS-207;   Biological: GVAX;   Drug: nivolumab;   Drug: CY
12 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
13 Not yet recruiting Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Biological: Nivolumab;   Other: Laboratory Biomarker Analysis
14 Recruiting Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Condition: Hematologic Neoplasms
Interventions: Drug: Ibrutinib;   Drug: Nivolumab
15 Not yet recruiting Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Conditions: Anal Canal Squamous Cell Carcinoma;   Metastatic Anal Canal Carcinoma;   Recurrent Anal Canal Carcinoma
Interventions: Biological: Nivolumab;   Other: Laboratory Biomarker Analysis
16 Recruiting A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: NY-ESO-1 157-165 (165V);   Drug: Nivolumab;   Biological: gp100:280-288 (288V);   Drug: Montanide ISA 51 vegetable grade (VG);   Drug: Ipilimumab;   Procedure: Apheresis Procedure
17 Recruiting A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Conditions: Melanoma;   Carcinoma, Non-Small-Cell Lung;   Colorectal Neoplasms;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   B Cell NHL or HL Including DLBCL
Intervention: Drug: Nivolumab + INCB24360
18 Recruiting A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
19 Recruiting A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Bevacizumab;   Biological: Ipilimumab
20 Recruiting A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Conditions: MSI Positive Colorectal Cancer;   MSI Negative Colorectal Cancer
Interventions: Drug: Ipilimumab;   Drug: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years